The mysterious case of Eli Lilly’s obesity drug

Who got exclusive access to Eli Lilly’s highly anticipated obesity candidate? And why are drugmakers spending so much on acquisitions? Find out on this week’s “Readout LOUD.”

View Post on Scour ↗

More from STAT on Scour.